GlassScriptPhysician profile
Jason Dinsmoor
NPI 1841602851
$439.54
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.30 · 2020: $25.61 · 2021: $327 · 2022: $65.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $53.37 | 2021-2022 | |
| Novo Nordisk INC | $46.72 | 2021 | |
| Amgen INC. | $41.75 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.27 | 2021 | |
| Esperion Therapeutics, INC. | $30.65 | 2021 | |
| Pfizer INC. | $26.75 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $25.00 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.77 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $23.63 | 2021 | |
| Glaxosmithkline, LLC. | $22.30 | 2019 | |
| Impel Pharmaceuticals INC. | $19.77 | 2022 | |
| Arbor Pharmaceuticals, INC. | $18.46 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.77 | 2021 | |
| Acadia Pharmaceuticals INC | $14.44 | 2020 | |
| Medtronic, INC. | $14.03 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.69 | 2021 | |
| Lilly USA, LLC | $11.17 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Dinsmoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.